Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Corbus Pharmaceuticals Hldgs Inc (CRBP)

Corbus Pharmaceuticals Hldgs Inc (CRBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 158,327
  • Shares Outstanding, K 12,179
  • Annual Sales, $ 0 K
  • Annual Income, $ -44,600 K
  • EBIT $ -46 M
  • EBITDA $ -45 M
  • 60-Month Beta 2.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.07

Options Overview Details

View History
  • Implied Volatility 86.99% ( +0.69%)
  • Historical Volatility 49.56%
  • IV Percentile 26%
  • IV Rank 14.15%
  • IV High 222.54% on 09/19/24
  • IV Low 64.65% on 11/21/24
  • Put/Call Vol Ratio 0.54
  • Today's Volume 122
  • Volume Avg (30-Day) 180
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 13,999
  • Open Int (30-Day) 14,079

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.30
  • Number of Estimates 7
  • High Estimate -1.02
  • Low Estimate -1.52
  • Prior Year -1.81
  • Growth Rate Est. (year over year) +28.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.90 +0.78%
on 12/19/24
18.89 -31.18%
on 12/02/24
-3.08 (-19.15%)
since 11/20/24
3-Month
12.90 +0.78%
on 12/19/24
23.33 -44.28%
on 09/26/24
-6.51 (-33.37%)
since 09/20/24
52-Week
5.09 +155.52%
on 12/21/23
61.90 -79.00%
on 07/31/24
+7.80 (+150.00%)
since 12/20/23

Most Recent Stories

More News
Corbus Pharmaceuticals Advances Oncology Research with First Patient Dosed in CRB-601 Clinical Trial for Advanced Solid Tumors

Corbus Pharmaceuticals begins Phase 1 trial for CRB-601, a monoclonal antibody targeting advanced solid tumors.Quiver AI SummaryCorbus Pharmaceuticals Holdings, Inc. recently announced the dosing of the...

CRBP : 13.00 (-2.48%)
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

CRBP : 13.00 (-2.48%)
2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential

With the growing demand for cutting-edge therapies reshaping the healthcare landscape, here are two “Strong Buy”-rated biotech stocks with significant potential upside.

VKTX : 42.25 (+1.83%)
CRBP : 13.00 (-2.48%)
NVO : 85.00 (-17.83%)
$SPX : 5,930.85 (+1.09%)
LLY : 767.76 (+1.35%)
Corbus Pharmaceuticals Receives FDA Fast Track Designation for CRB-701 in Treating Metastatic Cervical Cancer

Corbus Pharmaceuticals announced FDA Fast Track designation for CRB-701, targeting metastatic cervical cancer with a Phase 1 trial ongoing.Quiver AI SummaryCorbus Pharmaceuticals Holdings, Inc. announced...

CRBP : 13.00 (-2.48%)
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

CRBP : 13.00 (-2.48%)
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference

CRBP : 13.00 (-2.48%)
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

CRBP : 13.00 (-2.48%)
Corbus Pharmaceuticals: Q3 Earnings Snapshot

Corbus Pharmaceuticals: Q3 Earnings Snapshot

CRBP : 13.00 (-2.48%)
Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update

CRBP : 13.00 (-2.48%)
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

CRBP : 13.00 (-2.48%)

Business Summary

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic...

See More

Key Turning Points

3rd Resistance Point 13.86
2nd Resistance Point 13.66
1st Resistance Point 13.33
Last Price 13.00
1st Support Level 12.80
2nd Support Level 12.60
3rd Support Level 12.27

See More

52-Week High 61.90
Fibonacci 61.8% 40.20
Fibonacci 50% 33.49
Fibonacci 38.2% 26.79
Last Price 13.00
52-Week Low 5.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar